Drug intelligence / Profile preview

technetium-99m-H7ND

Development stage: Unknown
Lead developer: Beijing Farber Xintian Pharmaceutical Technology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

technetium-99m-H7ND is a radiopharmaceutical diagnostic agent under clinical development for SPECT imaging of fibroblast activation protein (FAP)-positive lesions in patients with solid tumors, particularly gastrointestinal malignancies. It is designed to target FAP-expressing tumor-associated fibroblasts for non-invasive detection and diagnosis of cancer metastases. The drug is currently being evaluated in clinical trials for its safety, pharmacokinetics, and efficacy in detecting peritoneal metastases in gastrointestinal cancer patients[1][2][5].

Other names: 锝[99mTc]-H7ND注射液[99mTc]-H7ND

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on technetium-99m-H7ND.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium-99m-H7ND.

Explore the full profile